Skip to main content
Clinical Trials/NCT00248820
NCT00248820
Unknown
N/A

Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

University Hospital, Tours1 site in 1 country100 target enrollmentSeptember 2002
ConditionsOvarian Tumor

Overview

Phase
N/A
Intervention
Not specified
Conditions
Ovarian Tumor
Sponsor
University Hospital, Tours
Enrollment
100
Locations
1
Primary Endpoint
From contrast-enhanced ultrasound: Enhancement parameters derived from time-intensity curves: time-to-peak, enhancement ratio, washout-time
Last Updated
18 years ago

Overview

Brief Summary

This study intends to assess the ability of contrast-enhanced ultrasound in the detection of benign and malignant ovarian masses compared to unenhanced ultrasound.

By using an intravascular contrast agent, this noninvasive and feasible imaging technique will allow the investigators to define specific microcirculation patterns in 100 women with ovarian lesions.

The intravascular contrast agent properties will be compared between benign and malignant adnexal masses.

The final purpose of this ultrasonography is to allow the early detection of tumors and to improve the characterization between benign and malignant lesions.

Detailed Description

SonoVue (Sulphur hexafluoride microbubbles) is a microbubbles preparation that is stable, resistant to pressure and specifically designed to be used as a contrast agent for ultrasound imaging. Study design : one contrast-enhanced ultrasonography is proposed before any surgery to patients with ovarian mass.

Registry
clinicaltrials.gov
Start Date
September 2002
End Date
February 2009
Last Updated
18 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Patient with adnexal mass detected by ultrasound
  • Any programmed surgery

Exclusion Criteria

  • Any contraindication to surgery
  • Injection of another contrast agent within 24 hours before the study examination
  • Pregnancy, breastfeeding
  • Patient known to have a coronary syndrome
  • Unstable angina and myocardial infarction
  • Acute cardiac failure, Class III/IV cardiac failure
  • Severe rhythm disorders
  • Acute endocarditis
  • Prosthetic valves
  • Patient previously having received an investigational drug within 30 days prior to admission into this study

Outcomes

Primary Outcomes

From contrast-enhanced ultrasound: Enhancement parameters derived from time-intensity curves: time-to-peak, enhancement ratio, washout-time

Time Frame: inclusion period

Secondary Outcomes

  • Histology assessments: microvessel density assessments and histological diagnosis(inclusion period)

Study Sites (1)

Loading locations...

Similar Trials